Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
Top Cited Papers
- 1 October 2008
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 135 (4) , 1176-1184
- https://doi.org/10.1053/j.gastro.2008.06.047
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Hypoadiponectinemia and NASH: Cause or effect?Gastroenterology, 2006
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialPublished by Elsevier ,2005
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsiesJournal of Hepatology, 2004
- Liver biopsy size matters in chronic hepatitis: Bigger is betterHepatology, 2003
- Improved Nonalcoholic Steatohepatitis After 48 Weeks of Treatment With the Ppar–γ Ligand RosiglitazoneHepatology, 2003
- Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitisJournal of Hepatology, 2003
- Pioglitazone Prevents Early-Phase Hepatic Fibrogenesis Caused by Carbon TetrachlorideBiochemical and Biophysical Research Communications, 2002
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆Gastroenterology, 1999
- Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factorsHepatology, 1990